Inclusion Criteria:

- Histological proven epithelial ovarian cancer, peritoneal cavity or fallopian tube
cancer (inclusive mucinous or clear cell tumors)

- Tumor over-expressing p53

- Progression of disease or relapse after previous therapy with platinum

- Measurable disease (RECIST 1.1) or elevated CA125 > 2 times the upper limit of normal
within 3 months and confirmed

- Age ≥ 18 years

- WHO performance status 0-2

- Adequate bone marrow function: WBC ≥ 3.0 x 109/l, neutrophils ≥ 1.5 x 109/l,
platelets ≥ 100 x 109/l

- Adequate liver function: bilirubin ≤ 1.5 x upper limit of normal (UNL) range, ALAT
and/or ASAT ≤ 2.5 x UNL, Alkaline Phosphatase ≤5 x UNL

- Adequate renal function: the calculated creatinine clearance should be ≥ 50 mL/min

- Survival expectation > 3 months

- Patients must be accessible for treatment and follow-up

- Written informed consent according to the local Ethics Committee requirements

Exclusion Criteria:

- Previous malignancy within 5 years, with exception of a history of a previous basal
cell carcinoma of the skin or pre-invasive carcinoma of the cervix.

- Serious other diseases as recent myocardial infarction, clinical signs of cardiac
failure or clinically significant arrhythmias

- Known hypersensitivity reaction to any of the components of the treatment

- Pregnancy or lactating

- Medical or psychological condition which in the opinion of the investigator would not
permit the patient to complete the study or sign meaningful informed consent